AOD-9604 dosage Calculator

• Low (0.25mg / 250mcg): Often utilized in localized administration models, such as intra-articular studies observing cartilage regeneration, or conservative baseline metabolic tracking.¹
• Mid (0.5mg / 500mcg): The median dosage frequently cited in in vivo studies observing sustained lipolytic effects without adverse metabolic interference (such as insulin resistance).²
• High (1.0mg / 1000mcg): The upper threshold typically used in acute study phases or subjects with higher total body mass. Trials evaluating fat oxidation have administered up to 1mg daily, demonstrating a strong safety and tolerability profile without inducing hyperglycemia.³
  

In established experimental protocols, AOD-9604 is almost universally administered once daily. Research generally stipulates administration in a fasted state (often in the morning before caloric intake) to maximize the peptide’s interaction with natural lipolysis windows, avoiding the insulin spikes that can blunt fat oxidation pathways.²

The standard route of administration in clinical literature is Subcutaneous (SubQ) injection for systemic lipolysis. Subcutaneous delivery provides a stable, predictable absorption rate into the systemic circulation. However, for specific orthopedic models (such as osteoarthritis repair), localized intra-articular administration has also been thoroughly documented.¹

Research literature indicates a variety of testing timelines depending on the primary endpoint:

• Acute Studies: 4 to 12 weeks to observe initial shifts in fat metabolism, plasma glycerol levels, or localized tissue repair.
• Longitudinal Studies: Up to 24 weeks. Extensive long-term testing has administered AOD-9604 continuously to observe sustained safety profiles, noting it does not induce anti-AOD-9604 antibodies, alter IGF-1 levels, or negatively impact overall insulin sensitivity over time.⁴

While AOD-9604 has a highly favorable safety profile—demonstrating no adverse effects on blood sugar, IGF-1, or cardiovascular markers in in vivo and in vitro models—it is not approved by the FDA for the treatment of obesity, weight loss, or joint repair. Its efficacy as a standalone therapeutic agent in human subjects requires further large-scale, double-blind clinical trials. All data provided is for educational reference, and all compounds are strictly for Research Use Only (RUO).

1. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432.https://pubmed.ncbi.nlm.nih.gov/26275694/
2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278.https://pubmed.ncbi.nlm.nih.gov/11146367/
3. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.https://pubmed.ncbi.nlm.nih.gov/11673763/
4. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.https://academic.oup.com/endo/article/142/12/5182/2988749